Blog

The rapid proliferation of wearable biosensors and Internet of Medical Things (IoMT) platforms has initiated a fundamental transformation in remote patient monitoring (RPM) and digital health. Historically, wearable technology operated as passive data collection endpoints, acquiring continuous physiological streams, such as electrocardiograms (ECG), photoplethysmography (PPG), pulse oximetry (text{SpO}_2), continuous glucose monitoring (CGM) and tri-axial accelerometry and transmitting raw data to centralised cloud infrastructure for processing. However, this centralised paradigm exhibits structural bottlenecks that constrain its efficacy in mission-critical medical scenarios. Cloud-centric analytics architectures inherently introduce substantial round-trip network latency, typically ranging from 1 to 3 seconds under stable conditions, and potentially stalling entirely in areas with limited connectivity. For time-sensitive clinical conditions, such as paroxysmal cardiac arrhythmias, sudden fall events in elderly patients, acute epileptic seizures, or rapidly developing hypoglycemic shock, a multi-second latency overhead severely impairs timely intervention.&nbsp; Furthermore, continuous raw data streaming from millions of wearers places an unsustainable burden on wireless network bandwidth and cloud computing infrastructure, while simultaneously elevating battery power consumption on the host wearable device due to sustained RF radio activation. In traditional cloud-centric frameworks, raw physiological streams are transmitted continuously via RF radios over cellular or wireless links to centralised internet servers where batch analytics produce delayed diagnostic feedback. In contrast, the edge-cloud hybrid model processes continuous sensor streams directly on local Tiny Machine Learning (TinyML) processors, generating real-time emergency alerts in under 150 milliseconds while transmitting only filtered metadata or significant anomalies back to cloud servers for longitudinal trend analysis. Data security and regulatory compliance present additional challenges to cloud-based physiological monitoring. Transmitting unencrypted or lightly encrypted sensitive biometrics across public wireless channels increases vulnerability to cyberattacks, unauthorised data interception and privacy breaches. This creates tension with stringent statutory regulations, including the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union. To resolve these operational limitations, the digital health paradigm is shifting toward "Edge AI" or "Edge Intelligence". By embedding machine learning (ML) models directly onto low-power microcontrollers (MCUs) and System-on-Chips (SoCs) integrated into wearable hardware, data analysis occurs locally at the point of generation. On-device inference eliminates round-trip cloud communication, compressing end-to-end processing latencies to sub-150 milliseconds or even sub-30 milliseconds depending on the model architecture. This structural evolution has established a hierarchical Edge-Cloud AI framework. Latency-sensitive tasks—such as noise filtering, feature extraction and real-time anomaly detection, are executed entirely within the wearable's local processing unit. Conversely, compute-heavy, non-time-sensitive workloads, including long-term longitudinal trend analysis, population-scale disease modelling, and global neural network retraining, are offloaded to the cloud. By transmitting only pre-filtered metadata or flagged clinical anomalies to remote servers, Edge AI architectures achieve up to a 90% reduction in wireless bandwidth requirements, extend wearable battery longevity and enforce zero-trust privacy boundaries by retaining raw physiological records locally on the user's device.Read the report in full <a href="https://www.healthcare.digital/single-post/edge-ai-in-wearable-technology-on-device-processing-means-health-data-can-be-interpreted-in-real-ti">https://www.healthcare.digital/single-post/edge-ai-in-wearable-technology-on-device-processing-means-health-data-can-be-interpreted-in-real-ti</a>

Edge AI in Wearable Technology: On-device processing means Health data can be interpreted in real time

The convergence of metabolic pharmacology and advanced biomedical engineering is driving a profound shift across the medical device landscape. While the rapid commercial expansion of injectable glucagon-like peptide-1 (GLP-1) receptor agonists has heightened global demand for intuitive drug delivery mechanisms, it has simultaneously catalysed a secondary market: continuous, non-invasive physiological monitoring.&nbsp; &nbsp;&nbsp; Moving beyond traditional rigid form factors such as smartwatches and wrist-worn fitness bands, the next growth frontier for medical device manufacturers lies in flexible, skin-conformal wearable systems. Built upon microfluidic networks, flexible substrates, microneedle arrays, and miniaturized bio-microelectromechanical systems (BioMEMS), these next-generation devices enable continuous biochemical and electrophysiological sensing directly from biofluids like interstitial fluid (ISF) and sweat. &nbsp;&nbsp; Although continuous glucose monitoring (CGM) represents the most commercially mature application of this technology, manufacturers are aggressively expanding into new clinical and wellness domains, including remote prenatal care and athletic biomarker tracking. However, market growth faces structural headwinds. Industry reporting highlights a stark adoption paradox: while 77 percent of U.S. physicians acknowledge the clinical utility of continuous wearable data, only 15 percent of their patients proactively demonstrate interest in sharing or utilizing these insights with their care teams. Unlocking the multi-billion dollar market for flexible medical wearables will require device manufacturers to address technical barriers surrounding signal stability, navigate complex electronic health record (EHR) integration, and bridge the behavioral disconnect between clinical intent and consumer adoption.Read the report in full <a href="https://www.healthcare.digital/single-post/paradigm-shift-in-medical-wearables-from-macro-electronics-to-flexible-biochemical-biosensors">https://www.healthcare.digital/single-post/paradigm-shift-in-medical-wearables-from-macro-electronics-to-flexible-biochemical-biosensors</a>

Paradigm Shift in Medical Wearables: From Macro Electronics to Flexible Biochemical Biosensors

The European healthcare technology (HealthTech) mergers and acquisitions (M&amp;A) landscape has entered a period of structured recalibration. Following post-pandemic market adjustments, current M&amp;A activity reflects a structural transition away from speculative growth toward high-conviction, disciplined transactions. Capital deployment is heavily concentrated in platforms demonstrating clear operational leverage, defensible reimbursement pathways and deep technological moats. &nbsp;&nbsp; Acquirers, comprising both private equity funds armed with substantial dry powder and strategic corporate buyers, are enforcing strict target criteria. A clear multi-tiered valuation dynamic has emerged: platforms meeting rigorous key performance indicators across financial efficiency, regulatory compliance, and cross-border interoperability command premium multiples, whereas underperforming or capital-inefficient startups face valuation compression.&nbsp; &nbsp;&nbsp; To achieve a successful exit in today's European market, HealthTech platforms must satisfy specific quantitative financial thresholds, national reimbursement frameworks, and emerging European regulatory mandates.Read the report in full <a href="https://www.healthcare.digital/single-post/quantifying-european-healthtech-m-a-readiness-key-valuation-multiples-financial-metrics-regulator">https://www.healthcare.digital/single-post/quantifying-european-healthtech-m-a-readiness-key-valuation-multiples-financial-metrics-regulator</a>

Quantifying European HealthTech M&A Readiness: Key Valuation Multiples, Financial Metrics, Regulatory Moats and Strategic Drivers

Nelson Advisors has been featured in the Harvard Business Review article 'The AI Revolution Won't Happen Overnight' referencing IBM Watson's cautionary tale of promises made with Healthcare AI solutions.Source: <a href="https://hbr.org/2025/06/the-ai-revolution-wont-happen-overnight">https://hbr.org/2025/06/the-ai-revolution-wont-happen-overnight</a>&nbsp;&nbsp; For all of the concern about AI’s biases, we tend to overlook our own, and this might be especially true in enterprise adoption. Enterprise AI isn’t plug-and-play. It collides with outdated systems, regulatory roadblocks, risk-averse corporate cultures, AI talent shortages, and procurement bottlenecks. The barriers aren’t technical, they’re systemic. It took us 100 years to add wheels to luggage, don’t underestimate the forces that balance the pace of technology diffusion. &nbsp;&nbsp; IBM Watson Health is a cautionary tale. IBM promised to “outthink cancer,” betting big that AI would transform healthcare. But by 2022, Watson was sold for parts, its potential crushed by messy, fragmented medical data, regulatory red tape, and real-world complexity. Hospitals found it unreliable. Doctors found it impractical. Ethical concerns mounted. Watson didn’t fail because of AI—it failed because IBM underestimated how difficult real-world implementation would be. &nbsp;&nbsp; AI will transform industries, just not at Silicon Valley speed. It will happen on enterprise time: longer, slower, and with far more friction than most expect. Companies that fall victim to bias and ignore these realities will waste resources, overpromise results, and erode trust. The winners in AI won’t be the ones making the boldest claims. They’ll be the ones with the patience to build real, lasting change.

Nelson Advisors featured in Harvard Business Review article: ‘The AI Revolution Won't Happen Overnight’

Nelson Advisors has been referenced in the NATO Association of Canada's article 'Canada’s Need For Binding AI Legislation Amidst Outsourcing Of Canadians Health Data'.Source: <a href="https://natoassociation.ca/canadas-need-for-binding-ai-legislation-amidst-outsourcing-of-canadians-health-data/">https://natoassociation.ca/canadas-need-for-binding-ai-legislation-amidst-outsourcing-of-canadians-health-data/</a>Canada regards universal healthcare as a national value and a point of sovereign pride, yet the data that powers it (the diagnoses, treatment notes, and intimate clinical conversations recorded by AI scribes etc.) are currently being processed through servers which fall under American law, with no binding Canadian standard for how it is stored or sold. The EU solved this problem with the 2024 AI Act and the 2025 European Health Data Space, but Canada’s answer, fourteen months after Bill C-27 died, is a ministerial task force and a voluntary code of conduct.Without coordinated action involving regulatory reform and strategic investment, aimed at reducing foreign dependency while building Canadian capability, Canadian medtech investment will leave, and the health AI ecosystem that the country can potentially &nbsp;own will be built elsewhere. As a result, Canada will not just continue to fall behind in the global technology race, but it will quietly surrender the infrastructure of its own healthcare sovereignty.&nbsp;Together, these two frameworks treat infrastructure and governance as a single coordinated act, not as sequential problems to be solved one at a time. The success is measureable, as Europe’s digital health market is currently valued at $96.68 billion and is projected to reach $222.22 billion by 2030. This is growth driven because of binding regulation, not despite it. And these exist as a piece of sovereign infrastructure that Canada has no equivalent of and currently no plan to build.&nbsp;<a href="https://nelsonadvisors.co.uk/blog/european-healthtech-and-medtech-m-a-predictions-for-2026">https://nelsonadvisors.co.uk/blog/european-healthtech-and-medtech-m-a-predictions-for-2026</a>

Nelson Advisors referenced in NATO Association of Canada article 'Canada’s Need For Binding AI Legislation Amidst Outsourcing Of Canadians Health Data'

The European HealthTech landscape is seeing key developments across funding, regulatory changes, and clinical implementations. &nbsp;&nbsp; Key Highlights &nbsp;&nbsp; 1. Mega-Funding &amp; Longevity Tech &nbsp;&nbsp; Neko Health’s $700M Series C: The preventative health scan startup co-founded by Spotify's Daniel Ek raised a massive $700 million Series C. With over 100,000 members and clinic-level profitability, Neko is expanding its full-body preventative diagnostic centers across Europe.Shift to Deep-Tech &amp; Medtech: Pure consumer wellness apps continue to take a back seat to clinical deep-tech. Notable recent raises include Azalea Vision securing up to €7.5 million through the EIC Accelerator for smart contact lenses that deliver non-invasive biomarker tracking, and Antwerp-based Sightera Bio raising €3 millionfor its AI drug discovery platform.&nbsp;2. Regulatory Alignment: EU AI Act vs. MDR Friction Compliance Pushback: HealthTech developers are grappling with the overlap between the newly implemented EU AI Act and the stringent Medical Device Regulations (MDR/IVDR). European Commission lobbying has intensified, with industry bodies estimating that streamlining these overlapping administrative frameworks could save the sector up to €3.3 billion annually.UK's Fast-Track Pivot: Seeking to capitalize on EU regulatory delays, the UK’s MHRA has introduced its "International Reliance" framework draft. This pathway lets medical device manufacturers leverage approvals from trusted global regulators to fast-track market entry into the UK.3. Clinical &amp; Operational AI Deployment Ambient Voice &amp; Workflow Automation: VC capital is flowing into "clinical plumbing" tools rather than front-facing patient apps. The European expansion of medical AI scribes (such as Tandem Health) is picking up steam to address clinician burnout.Data Interoperability: The European Innovation Council awarded its first €3.78 million across health data interoperability initiatives. These projects (including CARDIO-HUB for remote cardiac care) focus on breaking down fragmented data silos to build cross-border patient monitoring pipelines. &nbsp;&nbsp; &gt;&gt;&gt;&gt; &nbsp;&nbsp; The European MedTech sector saw several strategic shifts across regulatory alignment, digital health integration, and clinical device approvals. &nbsp;&nbsp; Key Developments &nbsp;&nbsp; 1. European Regulatory Alignment &amp; EMA Initiatives &nbsp;&nbsp; EMA &amp; EISMEA Innovation Bridge: The European Medicines Agency (EMA) and the European Innovation Council (EISMEA) formally launched a joint framework designed to help early-stage European health and MedTech innovators navigate regulatory pathways earlier in the development lifecycle. The initiative aims to reduce market-entry delays caused by regulatory friction under MDR/IVDR.EUDAMED Milestones: The mandatory rollout of the first four core modules of EUDAMED (the European database on medical devices) continues to re-shape operational workflows for device manufacturers. The shifting responsibilities—such as manufacturers directly handling master Summary of Safety and Clinical Performance (SSCP) uploads—are pushing medtech compliance teams toward greater data-handling automation.2. Surgical Robotics &amp; High-Complexity Integrations &nbsp;&nbsp; Spine &amp; AI Surgical Platforms: Italian MedTech player Masmec Biomed entered a strategic collaboration with Demetra Holding to combine surgical navigation, software, and AI into integrated spine surgery ecosystems. The deal underlines a broader industry trend where hardware manufacturers are prioritizing software and data integration over standalone hardware updates.Next-Gen Implants: A major milestone in non-invasive medtech occurred with new European approvals for vision-restoring ocular implants, alongside clinical expansion into AI-driven digital twin modelling for cardiovascular care.3. Supply Chain Resilience &amp; Sustainability Demands EU Eco-Design &amp; Packaging Shift: Beyond clinical requirements, European MedTech producers are adjusting to impending timelines under the EU Packaging and Packaging Waste Regulation (PPWR) and Ecodesign framework.Lifecycle assessments, supply chain traceability, and sustainable device materials are rapidly becoming core approval and purchasing requirements across European health systems.Procurement Strategy: Industry leaders at recent European summits have pushed back against "price-only" public procurement models. The emphasis is pivoting toward value-based procurement that rewards device longevity, patient outcomes, and supply-chain resilience in the face of ongoing global trade bottlenecks.The Takeaway: European MedTech is currently defined by a push toward integrated clinical platforms (hardware + AI), while navigating tighter sustainability mandates and mandatory EU digital databases. &nbsp; Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb" data-mce-href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>&nbsp; #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;&nbsp; Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&nbsp;<a href="mailto:paul@nelsonadvisors.co.uk" data-mce-href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>&nbsp; Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors

Blog

Edge AI in Wearable Technology: On-device processing mean...

Paradigm Shift in Medical Wearables: From Macro Electroni...

Quantifying European HealthTech M&A Readiness: Key Valuat...

Nelson Advisors featured in Harvard Business Review artic...

Nelson Advisors referenced in NATO Association of Canada ...

This Week in European HealthTech and MedTech: 24th July 2026